HLS Therapeutics Inc.（HLTRF）· 损益表

年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。

FMP · HLTRF · 截至 2026-06-09

财务报表

Revenue · Gross Profit · Net Income

Breakdown	2025-12	2024-12	2023-12	2022-12	2021-12
Revenue
Revenue	$56.47M	$56.62M	$63.07M	$61.47M	$60.01M
Cost of Revenue	$32.46M	$9.00M	$7.62M	$4.98M	$3.97M
Gross Profit	$24.01M	$47.62M	$55.45M	$56.49M	$56.04M
Gross Margin %(computed)	42.52%	84.11%	87.91%	91.90%	93.38%
Operating Expenses
R&D Expenses	$0.00M	$0.00M	$0.00M	$0.00M	$0.00M
G&A Expenses	$10.61M	$10.20M	$8.39M	$17.73M	$17.40M
Total Operating Expenses	$28.19M	$55.31M	$55.45M	$69.98M	$62.32M
Operating Income	($4.18M)	($7.69M)	($10.35M)	($13.44M)	($6.28M)
Operating Margin %(computed)	-7.40%	-13.57%	-16.41%	-21.87%	-10.47%
Interest Income	$0.11M	$0.30M	$0.35M	$0.06M	$0.04M
Interest Expense	$7.22M	$10.08M	$8.75M	$7.32M	$6.96M
Income Before Tax	($13.10M)	($15.58M)	($27.80M)	($23.72M)	($11.81M)
Income Tax Expense	($0.45M)	$4.07M	($0.27M)	($0.12M)	$1.31M
Net Income	($12.65M)	($19.66M)	($27.53M)	($23.60M)	($13.12M)
Net Margin %(computed)	-22.40%	-34.71%	-43.65%	-38.39%	-21.86%
Per Share & EBITDA
EPS (Basic)	$-0.40	$-0.62	$-0.85	$-0.73	$-0.41
Wtd Avg Shares	31.53M	31.84M	32.26M	32.43M	32.18M
EBITDA	$18.02M	$17.22M	$12.88M	$17.28M	$25.19M
EBITDA Margin %(computed)	31.91%	30.41%	20.43%	28.12%	41.97%